{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,31]],"date-time":"2026-08-31T16:58:05Z","timestamp":1788195485730,"version":"build-2803163510"},"reference-count":36,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2024,1,31]],"date-time":"2024-01-31T00:00:00Z","timestamp":1706659200000},"content-version":"unspecified","delay-in-days":30,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["RMD Open"],"accepted":{"date-parts":[[2024,1,17]]},"published-print":{"date-parts":[[2024,1]]},"abstract":"<jats:sec>\n                  <jats:title>Introduction<\/jats:title>\n                  <jats:p>Colchicine, commonly used in gout flare, is contraindicated in severe chronic kidney disease (CKD) (estimated glomerular filtration rate &lt;30\u2009mL\/min). However, in this context, there are few alternatives, and colchicine use persists. We evaluated the tolerance of colchicine and its efficacy in patients with severe CKD.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Patients and methods<\/jats:title>\n                  <jats:p>All prescriptions of colchicine for managing crystal-induced arthritis flare (gout or calcium pyrophosphate deposition (CPPD) disease) in a hospitalised patient with severe CKD were screened from September 2020 to September 2021. After patient consent and treatment information, clinical and biological safety and efficacy data were prospectively collected from day 1 (D1) to D11.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>We included 54 patients (median age 75 years (IQR 67\u201383)) with 62 colchicine prescriptions (cases). Twelve (22%) patients were on dialysis. The main reason for hospitalisation was heart failure (31.5%), acute renal failure (22.2%), infection (18.5%) or an acute joint episode (9.3%). In total, 59.3% of patients had diabetes. The prescriptions concerned 58 cases of gout flares, 1 case of CPPD and 3 cases of both. Initial colchicine dosages were \u22640.5\u2009mg\/day in 47\/62 (75.8%) cases; no dosage exceeded 1\u2009mg\/day (median duration of 6\u2009days (IQR 3\u201311)). Colchicine was well tolerated in 47\/61 (77%) cases. No serious adverse event was reported. Colchicine was considered completely effective by the medical team in 48\/58 (83%) of cases.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>The use of colchicine, at reduced doses, was mostly effective to treat crystal-induced arthritis flare in 54 patients with severe CKD and was well tolerated, without any serious adverse events.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1136\/rmdopen-2023-003872","type":"journal-article","created":{"date-parts":[[2024,1,31]],"date-time":"2024-01-31T23:00:25Z","timestamp":1706742025000},"page":"e003872","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":10,"title":["Safety and efficacy of colchicine in crystal-induced arthritis flare in 54 patients with severe chronic kidney disease"],"prefix":"10.1136","volume":"10","author":[{"given":"Johanna","family":"Bausson","sequence":"first","affiliation":[{"name":"Service de Pharmacie-St\u00e9rilisation, H\u00f4pitaux universitaires de Strasbourg, Strasbourg, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Keller","sequence":"additional","affiliation":[{"name":"Service de N\u00e9phrologie, H\u00f4pitaux universitaires de Strasbourg, Strasbourg, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Jacques","family":"Von Hunolstein","sequence":"additional","affiliation":[{"name":"Service de Cardiologie, H\u00f4pitaux universitaires de Strasbourg, Strasbourg, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthieu","family":"Sacrez","sequence":"additional","affiliation":[{"name":"Service de Pharmacie-St\u00e9rilisation, H\u00f4pitaux universitaires de Strasbourg, Strasbourg, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruno","family":"Michel","sequence":"additional","affiliation":[{"name":"Service de Pharmacie-St\u00e9rilisation, H\u00f4pitaux universitaires de Strasbourg, Strasbourg, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B\u00e9n\u00e9dicte","family":"Gourieux","sequence":"additional","affiliation":[{"name":"Service de Pharmacie-St\u00e9rilisation, H\u00f4pitaux universitaires de Strasbourg, Strasbourg, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Fourtage","sequence":"additional","affiliation":[{"name":"Service de Pharmacie-St\u00e9rilisation, H\u00f4pitaux universitaires de Strasbourg, Strasbourg, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4951-4032","authenticated-orcid":false,"given":"Renaud","family":"Felten","sequence":"additional","affiliation":[{"name":"Service de Rhumatologie de Hautepierre, RESO, Centre de R\u00e9f\u00e9rence des Maladies Autoimmunes Syst\u00e9miques Rares Est Sud-Ouest, H\u00f4pitaux universitaires de Strasbourg, Strasbourg, France"},{"name":"Centre d\u2019Investigation Clinique, Inserm 1434, H\u00f4pitaux Universitaires de Strasbourg, Strasbourg, France"},{"name":"D\u00e9partement Universitaire de Pharmacologie, Addictologie, Toxicologie et Th\u00e9rapeutique (DUPATT), H\u00f4pitaux Universitaires de Strasbourg, Strasbourg, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2024,1,31]]},"reference":[{"key":"2025090313492838000_10.1.e003872.1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2014.07.017"},{"key":"2025090313492838000_10.1.e003872.2","doi-asserted-by":"publisher","DOI":"10.1038\/nature04516"},{"key":"2025090313492838000_10.1.e003872.3","doi-asserted-by":"publisher","DOI":"10.1038\/ni.2550"},{"key":"2025090313492838000_10.1.e003872.4","first-page":"429","article-title":"Binding of colchicine and thiocolchicoside to human serum proteins and blood cells","volume":"32","author":"Sabouraud","year":"1994","journal-title":"Int J Clin Pharmacol Ther"},{"key":"2025090313492838000_10.1.e003872.5","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1097\/00007691-199404000-00012","article-title":"Radioimmunoassay of colchicine with antisera exhibiting variable cross-reactivity","volume":"16","author":"Sabouraud","year":"1994","journal-title":"Ther Drug Monit"},{"key":"2025090313492838000_10.1.e003872.6","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1016\/S0022-3565(25)10989-0","article-title":"Effect of cyclosporine on colchicine secretion by the kidney multidrug transporter studied in vivo","volume":"261","author":"Speeg","year":"1992","journal-title":"J Pharmacol Exp Ther"},{"key":"2025090313492838000_10.1.e003872.7","doi-asserted-by":"publisher","DOI":"10.1002\/art.30389"},{"key":"2025090313492838000_10.1.e003872.8","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2016-209707"},{"key":"2025090313492838000_10.1.e003872.9","doi-asserted-by":"publisher","DOI":"10.1002\/art.27327"},{"key":"2025090313492838000_10.1.e003872.10","doi-asserted-by":"crossref","first-page":"e523","DOI":"10.1016\/S2665-9913(23)00165-0","article-title":"Evaluating the safety and short-term equivalence of colchicine versus prednisone in older patients with acute calcium pyrophosphate crystal arthritis (COLCHICORT): an open-label, multicentre, randomised trial","volume":"5","author":"Pascart","year":"2023","journal-title":"Lancet Rheumatol"},{"key":"2025090313492838000_10.1.e003872.11","doi-asserted-by":"publisher","DOI":"10.1136\/annrheumdis-2013-203779"},{"key":"2025090313492838000_10.1.e003872.12","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2011.09.033"},{"key":"2025090313492838000_10.1.e003872.13","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-015-0610-9","article-title":"Gout and risk of chronic kidney disease and nephrolithiasis: meta-analysis of observational studies","volume":"17","author":"Roughley","year":"2015","journal-title":"Arthritis Res Ther"},{"key":"2025090313492838000_10.1.e003872.14","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2014-006843","article-title":"Chronic kidney disease as a risk factor for incident gout among men and women: retrospective cohort study using data from the Framingham heart study","volume":"5","author":"Wang","year":"2015","journal-title":"BMJ Open"},{"key":"2025090313492838000_10.1.e003872.15","doi-asserted-by":"publisher","DOI":"10.1681\/ASN.2007111256"},{"key":"2025090313492838000_10.1.e003872.16","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjmed.2014.12.010"},{"key":"2025090313492838000_10.1.e003872.17","doi-asserted-by":"publisher","DOI":"10.1016\/S0006-2952(96)00693-4"},{"key":"2025090313492838000_10.1.e003872.18","doi-asserted-by":"crossref","DOI":"10.1186\/s13075-021-02416-y","article-title":"Efficacy and safety of gout flare prophylaxis and therapy use in people with chronic kidney disease: a gout, hyperuricemia and crystal-associated disease network (G-CAN)-initiated literature review","volume":"23","author":"Pisaniello","year":"2021","journal-title":"Arthritis Res Ther"},{"key":"2025090313492838000_10.1.e003872.19","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1038\/s41584-021-00657-4","article-title":"Management of gout in chronic kidney disease: a G-CAN consensus statement on the research priorities","volume":"17","author":"Stamp","year":"2021","journal-title":"Nat Rev Rheumatol"},{"key":"2025090313492838000_10.1.e003872.20","doi-asserted-by":"publisher","DOI":"10.1086\/431592"},{"key":"2025090313492838000_10.1.e003872.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.transproceed.2012.09.028"},{"key":"2025090313492838000_10.1.e003872.22","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.krcp.2013.04.003","article-title":"Colchicine-induced myoneuropathy in a cyclosporine-treated renal transplant recipient","volume":"32","author":"Huh","year":"2013","journal-title":"Kidney Res Clin Pract"},{"key":"2025090313492838000_10.1.e003872.23","first-page":"515","article-title":"Acute colchicine intoxication during clarithromycin administration in patients with chronic renal failure","volume":"19","author":"Akdag","year":"2006","journal-title":"J Nephrol"},{"key":"2025090313492838000_10.1.e003872.24","first-page":"204","article-title":"Colchicine-induced neuromyopathy in a patient with chronic renal failure: the role of clarithromycin","volume":"66","author":"van der Velden","year":"2008","journal-title":"Neth J Med"},{"key":"2025090313492838000_10.1.e003872.25","doi-asserted-by":"crossref","first-page":"498","DOI":"10.5694\/j.1326-5377.2000.tb124076.x","article-title":"Fatal colchicine toxicity","volume":"172","author":"Kubler","year":"2000","journal-title":"Med J Aust"},{"key":"2025090313492838000_10.1.e003872.26","doi-asserted-by":"crossref","unstructured":"Solak Y , Acikgoz SB , Yildirim M . Colchicine toxicity: an exaggerated reality? Am J Med 2015;128. doi:10.1016\/j.amjmed.2015.02.020","DOI":"10.1016\/j.amjmed.2015.02.020"},{"key":"2025090313492838000_10.1.e003872.27","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/j.nephro.2019.07.204","article-title":"Utilisation de la colchicine chez les patients insuffisants r\u00e9naux s\u00e9v\u00e8res et\/ou dialys\u00e9s : \u00e9tat des lieux des pratiques","volume":"15","author":"Bausson","year":"2019","journal-title":"N\u00e9phrologie & Th\u00e9rapeutique"},{"key":"2025090313492838000_10.1.e003872.28","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1002\/acr.24180","article-title":"2020 American college of rheumatology guideline for the management of gout","volume":"72","author":"FitzGerald","year":"2020","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"2025090313492838000_10.1.e003872.29","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1053\/j.ajkd.2017.01.055","article-title":"Management of gout and hyperuricemia in CKD","volume":"70","author":"Vargas-Santos","year":"2017","journal-title":"Am J Kidney Dis"},{"key":"2025090313492838000_10.1.e003872.30","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.jbspin.2020.05.001","article-title":"2020 recommendations from the French Society of Rheumatology for the management of gout: management of acute flares","volume":"87","author":"Latourte","year":"2020","journal-title":"Joint Bone Spine"},{"key":"2025090313492838000_10.1.e003872.31","doi-asserted-by":"crossref","first-page":"100","DOI":"10.5414\/CN108343","article-title":"Colchicine toxicity in renal patients - Are we paying attention?","volume":"86","author":"Medani","year":"2016","journal-title":"Clin Nephrol"},{"key":"2025090313492838000_10.1.e003872.32","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1080\/15563650701779703","article-title":"Colchicine-induced toxicity in a heart transplant patient with chronic renal failure","volume":"46","author":"Eleftheriou","year":"2008","journal-title":"Clinical Toxicology"},{"key":"2025090313492838000_10.1.e003872.33","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1080\/00498254.2021.1909782","article-title":"Colchicine for the treatment of COVID-19 patients: efficacy, safety, and model informed dosage regimens","volume":"51","author":"Karatza","year":"2021","journal-title":"Xenobiotica"},{"key":"2025090313492838000_10.1.e003872.34","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-014-0238-6"},{"key":"2025090313492838000_10.1.e003872.35","doi-asserted-by":"crossref","first-page":"e189","DOI":"10.1097\/MJT.0b013e31825a364a","article-title":"Colchicine toxicity in end-stage renal disease patients: a case-control study","volume":"21","author":"Solak","year":"2014","journal-title":"Am J Ther"},{"key":"2025090313492838000_10.1.e003872.36","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.amjmed.2021.07.025","article-title":"Consensus statement regarding the efficacy and safety of long-term low-dose colchicine in gout and cardiovascular disease","volume":"135","author":"Robinson","year":"2022","journal-title":"Am J Med"}],"container-title":["RMD Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/rmdopen-2023-003872","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T20:49:36Z","timestamp":1756932576000},"score":1,"resource":{"primary":{"URL":"https:\/\/rmdopen.bmj.com\/lookup\/doi\/10.1136\/rmdopen-2023-003872"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,1,31]]},"published-print":{"date-parts":[[2024,1]]}},"alternative-id":["10.1136\/rmdopen-2023-003872"],"URL":"https:\/\/doi.org\/10.1136\/rmdopen-2023-003872","relation":{},"ISSN":["2056-5933"],"issn-type":[{"value":"2056-5933","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,1]]}}}